Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
LAVA Therapeutics N.V. LVTX
$1.84
-$0.05 (-2.86%)
На 18:04, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
46794598.00000000
-
week52high
7.38
-
week52low
1.37
-
Revenue
19391000
-
P/E TTM
-4
-
Beta
-0.49778800
-
EPS
-1.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 22 дек 2021 г. |
| SVB Leerink | Outperform | 19 апр 2021 г. | |
| JP Morgan | Overweight | 19 апр 2021 г. | |
| Jefferies | Buy | 19 апр 2021 г. | |
| SVB Leerink | Outperform | Outperform | 16 ноя 2021 г. |
| SVB Leerink | Outperform | Outperform | 17 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
GlobeNewsWire
23 янв 2023 г. в 07:00
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023.
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference.
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?
Zacks Investment Research
25 ноя 2022 г. в 11:17
The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock.
LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates
Zacks Investment Research
16 ноя 2022 г. в 18:48
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022.
LAVA Therapeutics: Assessing A Promising Innovator
Seeking Alpha
18 окт 2022 г. в 02:32
LAVA is able to form a highly profitable partnership with Seagen to develop LAVA-1223 for various solid tumors. The company's Gammabody platform holds strong promises as a delivery vehicle for a differentiated type of cellular therapy.